Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

Clinical and Experimental Immunology

Volumn 117, Issue 3, 1999, Pages 496-503

  Poltl Frank F ^d   Zurbriggen, R ^a   Helg, A ^d   Stuart, F ^b   Robinson, J ^b   Gluck R ^a   Pluschke, Gerd ^c  

^a Berna Biotech AG   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d NONE

Author keywords

Delivery; Malaria peptide vaccine; Virosomes

Indexed keywords

MALARIA VACCINE;

ANIMAL CELL; ARTICLE; DRUG DELIVERY SYSTEM; GENE SEQUENCE; IMMUNOFLUORESCENCE TEST; IMMUNOPOTENTIATION; INFLUENZA VIRUS; MALARIA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; CROSS REACTIONS; DNA, COMPLEMENTARY; DRUG DELIVERY SYSTEMS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; LIPOSOMES; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0006981144     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00989.x     Document Type: Article

References (30)

1. 1 Patarroyo ME, Romero P, Torres ML et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987; 328:629-32.
2. 2 Lopez MC, Silva Y, Thomas MC et al. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. Vaccine 1994; 12: 585-91.
3. 3 Facer CA, Tanner M. Clinical trials of malaria vaccines: progress and prospects. Adv Parasitol 1997; 39:1-68.
4. 4 Graves P, Gelbrand H, Garner P. The SPf66 malaria vaccine: what is the evidence for efficacy? Parasitol Today 1998; 14:218-20.
5. 5 Valero MV, Amador LR, Galindo C et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993; 341:705-10.
6. 6 Valero MV, Amador R, Aponte JJ et al. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 1996; 14:1466-70.
7. 7 Noya O, Gabaldon Berti Y, Alarcon de Noya B et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 1994; 170: 396-402.
8. 8 Sempertegui F, Estrella B, Moscoso J et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 1994; 12:337-42.
9. 9 Alonso PL, Smith T, Schellenberg JR et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344:1175-81.
10. 10 D'Alessandro U, Leach A, Drakeley CJ et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995; 346:462-7.
11. 11 Nosten F, Luxemburger C, Kyle DE et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in north-western Thailand. Shoklo Spf66 Malaria Vaccine Trial Group. Lancet 1996; 348:701-7.
12. 12 Schild H, Rammensee H-G. Peptide based vaccines. In: Kaufmann SHE, ed. Concepts in vaccine development. Berlin: Walter de Gruyter, 1996:303-25.
13. 13 Engers HD, Godal T. Malaria vaccine development: current status. Parasitol Today 1998; 14:56-64.
14. 14 Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, Hill AV. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997; 15:1280-4.
15. 15 Glück R. Liposomal presentation of antigens for human vaccines. Pharm Biotechnol 1995; 6:325-45.
16. 16 Glück R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992; 90:2491-5.
17. 17 Tsurudome M, Glück R, Graf R, Falchetto R, Schaller U, Brunner J. Lipid interactions of the hemagglutinin HA2 NH2-terminal segment during influenza virus-induced membrane fusion. J Biol Chem 1992; 267:20225-32.
18. 18 Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glüek R, Herzog C. Immunogenicity and protectively of a new liposomal hepatitis A vaccine. Vaccine 1997; 15:1209-13.
19. 19 Stüber D, Bannwarth W, Pink JR, Meloen RH, Matile H. New B cell epitopes in the Plasmodium falciparum malaria circumsporozoite protein. Eur J Immunol 1990; 20:819-24.
20. 20 de St. Groth SF, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980; 35:1-21.
21. 21 Matile H, Pink R. Plasmodium falciparum malaria parasite cultures and their use in immunology. In: Lefkovits I, Pernis B, eds. Immunological methods, Vol. IV. San Diego: Academic Press, 1990:221-34.
22. 22 Leung SO, Dion AS, Pellegrini MC, Goldenberg DM, Hansen HJ. An extended primer set for PCR amplification of murine kappa variable regions. Biotechniques 1993; 15:286-92.
23. 23 Lefrane M-P, Giudicelli V, Busin C et al. IMGT, the international ImMunoGeneTics database. Nucl Acids Research 1998; 26:297-303.
24. 24 Karlsson R, Mo JA, Holmdahl R. Binding of autoreactive mouse anti-type II collagen antibodies derived from the primary and the secondary immune response investigated with the biosensor technique. J Immunol Methods 1995; 188:63-71.
25. 25 Neri D, Montigiani S, Kirkham PM. Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol 1996; 14:465-70.
26. 26 Neurath AR, Kent SBH, Strick N. Antibodies to hepatitis B surface antigen (HbsAG) elicited by immunizing with a synthetic peptide covalently linked to liposomes. J Gen Virol 1984; 65:1009-14.
27. 27 Lifshitz R, Gitler C, Moses E. Liposomes as immunologies adjuvants in eliciting antibodies specific to the synthetic polypeptide poly (LTyr.LGlu)-poly (DLAIa)-poly (LLys) with high frequency of site associated idiotypic determinants. Eur J Immunol 1981; 11:398-404.
28. 28 Zurbriggen R, Glück R. Immunogenicity of 1R1V-versus alumadjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 1999; 17:1301-5.
29. 29 Rocha CL, Murillio LA, Mora AL et al. Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf66. Parasite Immunol 1992; 14:95-109.
30. 30 Salcedo M, Barreto L, Rojas M, Moya R, Cote J, Patarroyo MK. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol 1991; 84:122-8.